SCHEMBL6777556

SCHEMBL6777556

N[C@H](CSc1ccccc1)CC(=O)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC15A1 P46059 2/20 0.50
ALDH1A1 P00352 3/20 0.49
MAPK1 P28482 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CDC25B P30305 1/20 0.48
CASP1 P29466 1/20 0.46
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
CA2 P00918 1/20 0.42
KMT2A Q03164 2/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
EGFR P00533 1/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
SLC1A3 P43003 2/20 0.40
SLC1A2 P43004 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25711775 1.00 SLC15A1 (0.50) SLC15A1ALDH1A1MAPK1L3MBTL1CDC25B
Hydrochloric Acid SCHEMBL19511476 0.83 ALDH1A1 (0.59) SLC15A1ALDH1A1MAPK1L3MBTL1CDC25B
SCHEMBL6840772 0.82 ALDH1A1 (0.47) SLC15A1ALDH1A1MAPK1L3MBTL1CDC25B
SCHEMBL554680 0.81 MAOA (0.50) ALDH1A1L3MBTL1MAOAMAOBKMT2A
SCHEMBL554681 0.81 MAOA (0.50) ALDH1A1L3MBTL1MAOAMAOBKMT2A
SCHEMBL4624347 0.80 ALDH1A1 (0.56) SLC15A1ALDH1A1MAPK1L3MBTL1CDC25B
SCHEMBL20364073 0.80 ALDH1A1 (0.56) SLC15A1ALDH1A1MAPK1L3MBTL1CDC25B
SCHEMBL6822910 0.80 ALDH1A1 (0.56) SLC15A1ALDH1A1MAPK1L3MBTL1CDC25B
SCHEMBL14119359 0.80 SLC15A1 (0.63) SLC15A1ALDH1A1MAPK1L3MBTL1CDC25B
SCHEMBL28704585 0.80 SLC15A1 (0.63) SLC15A1ALDH1A1MAPK1L3MBTL1CDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed